Center for Clinical and Translational Science

摘要 新型SARS-COV-2病毒引发的大流行继续对健康产生破坏性影响， 临床上，社会上和经济上的。预防方法需要了解 一般人群的病毒流行率和群体免疫水平。作为先前自然历史的一部分 研究，临床和转化科学中心（CCTS;伯明翰亚拉巴马大学[UAB]） 与匹兹堡大学临床和转化科学研究所（CTSI）和 国家过敏和传染病研究所（NIAID）传染病实验室（LID） 协调国家COVID-19血清阳性项目。这项研究建立了一个近代表性的，国家- 11，300名未被诊断出感染病毒的参与者组成的广泛队列， 评估全美的基本免疫力为了检查与时间相关的人群患病率， SARS-COV-2的可检测抗体，这个学术医学中心和NIH的科学合作伙伴关系， 校内研究计划将召回并重新同意已建立的队列提交额外的血液 从最初入组日期至 了解全国各地COVID-19免疫力的变化（目标1）。新获得的生物标本将 用于确定与健康结果相关的免疫属性，包括特殊或 代表性不足的人群和个人在整个生命过程中（目标2）。这项工作得益于 在传染病基础和应用研究以及病毒疫苗开发、宿主 美国国家过敏和免疫研究所的病毒免疫反应、病毒分子生物学和遗传学， 传染病（NIAID）。它还利用了临床和 转化科学奖（CTSA）在UAB和匹兹堡的中心，以迅速吸引不同的群体， 参与者在全国范围内加速转化研究，这在科学上是高度优先的， 公共卫生实践。从这项研究中，合作团队将获得对纵向 我们将评估COVID-19疫情在全国的影响，并将确定疫苗的潜在目标。这些 数据对于评估公共卫生工作的影响和指导持续的COVID-19应对至关重要。

ABSTRACT The pandemic prompted by the novel SARS-COV-2 virus continues to have a devastating impact on the health of communities, clinically, socially and economically. Preventive approaches require an understanding of the virus prevalence and the level of herd immunity in the general population. As part of a previous natural history study, the Center for Clinical and Translational Science (CCTS; University of Alabama at Birmingham [UAB]) collaborated with the University of Pittsburgh Clinical and Translational Science Institute (CTSI) and the National Institute of Allergy and Infectious Diseases (NIAID) Laboratory of Infectious Disease (LID) to coordinate a national COVID-19 seroprevalence project. This study established a near-representative, nation- wide cohort of 11,300 participants who had not been diagnosed with the virus to provide biospecimens to evaluate baseline immunity across the United States. To examine the time-dependent population prevalence of detectable antibodies to SARS-COV-2, this scientific partnership of academic medical centers and the NIH’s intramural research program will recall and re-consent the established cohort to submit additional blood specimens and clinical information at 6- and 12-month time points from their original enrollment date to understand changes in COVID-19 immunity across the country (Aim 1). Newly obtained biospecimens will be used to determine the immune attributes associated with health outcomes, including outcomes in special or underrepresented populations and individuals across the life course (Aim 2). This work benefits from the deep expertise in the basic and applied research of infectious diseases as well as viral vaccine development, host immune response to viruses, and viral molecular biology and genetics at the National Institute for Allergy and Infectious Diseases (NIAID). It also leverages the rigorous and efficient capacity maintained by Clinical and Translational Science Awards (CTSA) Hubs at UAB and Pittsburgh to rapidly engage diverse cohorts of participants nationally to accelerate translational research that is high priority scientifically and for eventual public health practice. From this study, the collaborative team will gain crucial insights into the longitudinal impact of the COVID-19 pandemic across the country and will identify potential targets for a vaccine. These data are essential to assess the impact of public health efforts and to guide ongoing COVID-19 response.